CP
BCRX icon

Caligan Partners’s BioCryst Pharmaceuticals BCRX Stock Holding History

Caligan Partners’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-638,908
Closed -$5.72M – 19
2025
Q2 		$5.72M Sell
638,908
-2,468,761
-79% -$23M 1.1% 13
2025
Q1 		$23.3M Buy
3,107,669
+111,737
+4% +$901K 4.86% 7
2024
Q4 		$22.5M Buy
2,995,932
+412,347
+16% +$3.13M 5.71% 6
2024
Q3 		$19.6M Sell
2,583,585
-2,015,152
-44% -$15.3M 6.22% 7
2024
Q2 		$28.4M Buy
4,598,737
+3,840,235
+506% +$21.2M 6.64% 5
2024
Q1 		$3.85M Buy
+758,502
New +$4.27M 1.02% 11

Other funds holding BCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Caligan Partners's BCRX Position: Q3 2025 in Review

Caligan Partners sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2025, closing a stake of 638,908 shares — an estimated $5.72M sold.

Caligan Partners first reported a position in BCRX in Q1 2024 and held it in 6 quarters. The position peaked at $28.4M in Q2 2024. 286 funds tracked by Wall St. Rank hold BCRX as of Q3 2025.

  • Caligan Partners reported no remaining BioCryst Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Caligan Partners sold 638,908 BioCryst Pharmaceuticals shares in Q3 2025, an estimated $5.72M.
  • Caligan Partners first reported a position in BioCryst Pharmaceuticals in Q1 2024 and held it in 6 quarters.
  • Caligan Partners's BioCryst Pharmaceuticals position peaked at $28.4M in Q2 2024.
  • 286 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2025.

Based on Caligan Partners's 13F filing for Q3 2025, filed 14 Nov 2025.